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Background: There are few clinical trials that assess the efficacy of antihistamines in very 
young children. Rupatadine is a second-generation antihistamine indicated for the treatment of 
allergic rhinitis (AR) and urticaria. In this study, AR symptoms were evaluated before and after 
daily 1 mg/mL rupatadine oral solution administration in 2–5-year-old children.
Methods: A multicenter open-label study was carried out in 2–5-year-old children with AR. 
Safety assessments were collected during the study including spontaneous adverse events, vital 
signs, and electrocardiogram (QTc interval). Additionally, evaluations of Total Five Symptoms 
Score (T5SS, including: nasal congestion; sneezing; rhinorrhoea; itchy nose, mouth, throat, and/
or ears; and itchy, watery, and red eyes) were analyzed. Symptoms were evaluated by parents/legal 
guardian before and after 4 weeks of rupatadine administration, dosed according to body weight.
Results: A total of 44 children received the study treatment. Only 15 adverse events were 
reported. All of them were of mild intensity and considered not related to the study treatment. 
No patient exceeded the standard parameter of >450 ms in the last visit, for the QTc interval 
on their electrocardiograms. From a maximum score value of 15, T5SS values at Day 14 (6.35) 
and Day 28 (5.42) were both statistically significant different (p<0.001) from the baseline T5SS 
value (mean 8.65), with a reduction of 26.6% and 37.4%, respectively. All individual symptoms, 
including nasal congestion, showed also a decrease from baseline at both 14 and 28 days.
Conclusion: Rupatadine 1 mg/mL oral solution was found to be safe in 2–5-year-old children, 
correlating with an improvement of AR symptoms, overall and each individually, after a daily 
dose administration. With this study, we enlarge the available information in this very young 
pediatric patients’ group, in which there is a general lack of clinical evidence.
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Introduction
Allergic rhinitis (AR) is increasing worldwide, particularly in industrialized regions. 
Although it is not a severe disease, it can cause a large impact in quality of life and, 
especially in children, impair their performance in learning activities.1,2 AR is the 
most prevalent chronic allergic disease in children, and although it is most prevalent 
in school-age children, its prevalence and importance in younger children are signifi-
cant.3,4 In a birth cohort study in the Isle of Wight, it was shown that AR symptoms 
appear early in life, and increase over the age, from 3.4% at 4 years to 27.3% at 18 
years.5 Prevalence of rhinitis with itchy watery eyes (ie, allergic rhinoconjunctivitis) 
in children 6–7 and 13–14 years old has been extensively studied in the ISAAC study, 
with a prevalence of 8.5% and 14.6%, respectively.6 However, prevalence of AR in 
preschool children is difficult to evaluate, as symptoms may be confused with upper 
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airway infectious diseases and clinical endpoints are difficult 
to be evaluated although they are the ones recommended in 
the guidelines. Some cross-sectional studies in early child-
hood demonstrated that AR was diagnosed by physicians 
in 2.8% of 2–6-year-old children in People’s Republic of 
China and 3.9% in 5–6-year-old children in Germany.7,8 
PARIS, a prospective birth cohort study, was implemented in 
2003 to assess environmental/behavioral factors associated 
with respiratory and allergic disorder occurrence in early 
childhood in 5 Paris maternity hospitals.9 Data on AR-like 
symptoms (runny nose, blocked nose, and sneezing apart 
from a cold) were collected using a standardized question-
naire administered during the health examination at age 18 
months and was included in the follow-up of the PARIS birth 
cohort  to assess the prevalence of AR-like symptoms in the 
past year, which was found to be 9.1% of the 1,850 toddlers 
of the study cohort. AR-like symptoms and dry cough apart 
from a cold were frequent comorbid conditions. The results 
of this study support the hypothesis that AR could begin as 
early as 18 months of life.10
Very young children need safe and efficacious drugs 
that treat AR symptoms, enabling them to keep up with the 
learning requirements of that time of life. In this regard, 
major AR guidelines have been developed from evidence 
obtained in adults, not in children, although the same thera-
peutic approach is recommended, with antihistamines being 
the cornerstone of treatment for children suffering from this 
condition.3,11 However, there are a few clinical studies with 
second-generation antihistamines evaluating the efficacy in 
very young children.12–14
Rupatadine is a H1 receptor antagonist and platelet 
antagonist factor (PAF) antagonist indicated for the treat-
ment of AR and urticaria in adults and children >2 years. 
Several mediators are implied in the inflammatory cascade, 
with histamine the most relevant of them. PAF has a role in 
the inflammatory cascade, and so blocking PAF might have 
additional effects to the antihistamine action of rupatadine.15
In a previous, double-blind, randomized, placebo-controlled 
trial in persistent AR, rupatadine was the first anti-H1 com-
pound to assess its efficacy and safety following Allergic rhinitis 
and its Impact on Asthma (ARIA) recommendations in pediatric 
patients aged 6–11 years.16 This current paper adds clinical 
information in 2–5-year-old children, assessing AR symptoms.
Methods
This was a 28-day open-label, multicenter study in children 
aged 2–5 years, conducted in Hungary and South Africa. 
To be enrolled in this study, children must weigh ≥10 kg 
and must have a history of mild to moderate AR defined as 
either intermittent or persistent according to ARIA guide-
line.3 Children had to be symptomatic with a baseline of 5 
symptoms score: Total Five Symptoms Score (T5SS: nasal 
congestion; sneezing; rhinorrhea; itchy nose, mouth, throat, 
and/or ears; and itchy, watery, and red eyes score) ≥6 during 
each of the last 2 days before of inclusion, and allergen skin 
prick test positive wheal of 3 mm greater than the diluent 
control, or a positive (class 3 of positivity; ≥3.5–17.5 kU/L) 
on ImmunoCAP® test (Phadia, Uppsala, Sweden). They 
were required to have normal results for standard labora-
tory tests and a 12-lead electrocardiogram (ECG) obtained 
at screening (Day –7 to 0) within acceptable limits. QTc 
interval values (ms) after Fridericia’s correction had to be 
normal (<450 ms). Prolongation of the QTc interval on 
the ECG and the development of torsades de pointes-type 
arrhythmias were reported in the literature for astemizole 
and terfenadine during the 1990s, and this has led to wider 
concern regarding the cardiotoxic potential of the second 
generation of antihistamines. For this reason, cardiac safety 
is closely monitored in these types of products. Informed 
consent was obtained from the patient’s parents or legal 
guardians, before inclusion in the study.
Children with a history of chronic sinusitis or severe 
bronchial asthma, nonallergic rhinitis, chronic nasal or 
upper respiratory symptoms/disorders, nasal polyps, and 
significant deviation of nasal septum were not eligible. 
None of the children had suffered any ear, nose, or throat 
infection in the 15 days prior to the baseline. Patients were 
not permitted to take systemic or topical medication for AR 
for a wash-out period prior to inclusion, as follows: oral and 
nasal corticosteroids (28 days), nasal decongestants (3 days), 
cromones (14 days), leukotriene inhibitors (3 days); oral/topi-
cal H1-receptor antagonists (7 days); H1- and H2-receptor 
antagonists: doxepin (7 days); leukotriene antagonists (4 
days), anticholinergics (3 days); ophthalmic nonsteroidal 
anti-inflammatory drugs (3 days); nasal– ophthalmic wash 
solutions (12 h); tricyclic antidepressants (30 days); and/or 
any drug interacting with CYP3A4. Inhaled β
2
 bronchodila-
tors were permitted. Children with mild asthma treated with 
inhaled corticosteroids of ≤250 µg/d for fluticasone, ≤400 
µg/d for budesonide, or ≤160 µg/d for ciclesonide were 
allowed in the study.
The study had a duration of 28 days scheduled in 3 visits: 
baseline (Visit 0), treatment day 14 (Visit 1), and a final visit 
after 28 days (Visit 2). Rupatadine 1 mg/mL oral solution (J 
Uriach y Compañía, S.A., Spain) was given at a dose of 2.5 
mL in children with a body weight ≥10 kg up to <25 kg and 
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at a dose of 5 mL in children ≥25 kg. The medication was 
dispensed using a graduated syringe of 5 mL.
Safety was evaluated by means of data collection on 
adverse events and by assessing clinically relevant changes 
in physical examination and vital signs at each visit. ECG 
(QTc/QTcF) and laboratory tests were done at screening and 
final visit (Visit 2). A paired Student’s t-test was used in order 
to compare values between the 2 visits.
Referring to efficacy assessment, daily evaluation was 
made by the parents/legal guardians in a reflective way by 
means of a “Patient Diary Card.” Symptoms were assessed 
using a 4-grade scale ranging as follows: (0) = absent; (1) = 
mild: (symptom is present but not annoying); (2) = moder-
ate: (symptom is annoying but does not interfere with daily 
activity); and (3) = severe: (symptom interferes with daily 
activity or sleep). The maximum possible value for T5SS 
would be 15. Symptoms were collected from baseline and 
during the whole treatment period. Parents/legal guardians 
were advised to fill in the diary cards at the same time of 
the day to ensure homogeneity of the reflective assessment.
The efficacy endpoint consisted in evaluating the change 
from baseline in the T5SS after 14 and 28 days of treatment. 
The time to beginning of action was considered as the first day 
in which any significant difference was observed for T5SS.
Overall impression of efficacy was also assessed based on 
investigator’s criteria on days 14 and 28. The following scale 
was used: (0): increase in symptom intensity; (1): no changes in 
symptom intensity; (2): slight improvement in symptom inten-
sity; (3): significant symptom improvement; and (4): excellent 
improvement or complete disappearance of symptoms.
Blood samples were also taken to perform a population 
pharmacokinetic analysis, which will be reported in a sepa-
rate publication.
Drug compliance was checked at Visit 1 and Visit 2 by 
questioning the parents/legal guardians on how many days 
they forgot to administer the dose. Patients who missed less 
than or equal to 4 doses (either consecutive or not) were 
considered to have good compliance.
A paired Student’s t-test (significant level: α=0.05) was 
used to detect differences. Linear interpolation was used to 
estimate missing data from diary missing values (for each 
symptom) and last observation carried forward  was applied 
in withdrawn patients. The safety and efficacy analysis were 
performed using SAS software (v.8.2) (SAS Institute Inc., 
Cary, NC, USA).
The study (EudraCT: 2012-004900-37) was performed in 
compliance with the Declaration of Helsinki and was a part of 
the completed Paediatric Investigation Plan (EMEA-000582-
PIP01-09). The study was approved by Regulatory Authori-
ties and the central Ethics Committee in Hungary (National 
Institute of Pharmacy) and local Ethics Committees in South 
Africa (The University of Cape Town and Pharma Ethics)
Results
A total of 49 patients were screened, from which 5 were did 
not fulfill all the inclusion/exclusion criteria: 1 patient had 
T5SS <6 and 4 had an infection. Thus, 44 children were allo-
cated to the study treatment and considered for safety, and in 
43 of them efficacy analysis was done; this was because one 
child discontinued the study due to intake of prohibited con-
comitant medication. The study was carried out in 5 centers 
distributed between South Africa (3) and Hungary (2). The 
parents or legal guardians provided written informed consent 
before the study beginning. The majority of patients were 
sensitive to house dust mite. The sample was recruited very 
shortly and the total number of subjects was selected between 
January and February, which meant that it was summer in 
South Africa and winter in Hungary. The main demographic 
and baseline characteristics are shown in Table 1.
The 44 included children were generally in good health. 
The most frequent previous or concurrent diseases were 
eczema (40.9% of patients) and asthma (36.4% of patients).
Baseline symptom values were of mild to moderate 
intensity, with a mean (SD) T5SS of 8.65 (1.84). The mean 
of individual symptoms scores at baseline was 1.88 (0.67) 
for nasal congestion; 1.92 (0.52) for sneezing; 1.81 (0.71) for 
rhinorrhea; 1.87 (0.72) for itchy nose, mouth, throat, and/or 
ears; and 1.16 (0.73) for itchy, watery, and red eyes.
Table 1 Demographic and other baseline characteristics
Variable Mean (SD), N=44
Sex (male)a 24 (54.6%)





Height (m) 1.00 (0.09)
Weight (kg) 15.3 (3.07)
BMI (kg/m2) 15.3 (1.85)
Allergen distributiona,b
House dust mite 32 (78.8%)
Grass 24 (58.5%)
Pets 4 (9.8%)
Fungal spores 12 (29.3%)
T5SS 8.65 (1.84)
Note: an (%); b1 patient may be positive for 1 or more allergen.
Abbreviations: BMI, body mass index; T5SS, Total Five Symptoms Score.





Assessing the adherence to treatment, it was found that 
all of them (100.0%) did not miss 4 doses throughout treat-
ment period.
Safety
There were only 15 adverse events reported in 11 patients 
(25%). The list of the reported adverse events is summarized 
in Table 2. Out of the 15 events, 10 (66.7%) were of mild, 4 
(26.7%) of moderate, and 1 (6.7%) was of severe intensity. 
Only viral infection (20.0%) and conjunctivitis (13.3%) were 
reported in >1 patient. None of these adverse events were 
considered related to the study medication, and there were 
no serious adverse events reported in this study.
One patient showed a biochemistry with clinically rel-
evant abnormal value for creatine kinase, 718.0 U/L. This 
patient suffered a viral infection considered mild during this 
period of time. The creatine kinase increase was considered 
not serious and not related to the study drug by the investiga-
tor. No action was taken, and the patient recovered.
There were no statistically significant differences for any 
of the vital signs, except for weight, where a statistically sig-
nificant increase was observed (p<0.001) with a mean (SD) 
value at the end of study of 15.68 (2.95) kg. This mean dif-
ference of <300 g cannot be considered as clinically relevant, 
as children in the growing age were the target population of 
the study.
No abnormalities were found when QT and QTcF >450 
ms were assessed at Visit 2 with respect to screening visit.
Efficacy
T5SS values at Day 14 (6.35) and Day 28 (5.42) were both 
statistically significant lower (p<0.001) than the baseline 
value of 8.56 (1.84), as presented in Figure 1. These values 
represented a considerable decrease from baseline T5SS with 
a percentage of 26.6% and 37.4% of reduction at 14 and 28 
days, respectively.
Mean absolute values of each individual daily symptom 
score  measured at baseline and Days 14 and 28 are presented 
for each of the symptoms in Figure 2. Each individual symp-
tom’s daily symptom score showed a statistically significant 
decrease (p<0.01) after both 14 and 28 days of treatment. 
Nasal congestion showed a reduction of 20.2% and 32.3%; 
sneezing 32.4% and 42.9%; rhinorrhoea 20.9% and 30.7%; 
itchy nose, mouth, throat, and/or ears symptoms 32.3% and 
43.1%; and itchy, watery, and red eyes 26.9% and 37.6%, at 
Days 14 and 28, respectively.
The mean daily evolution of T5SS during 28 study days 
is presented in Figure 3, which shows a decrease in T5SS 
maintained during the whole treatment period. In terms of 
onset of action, statistically significant differences in T5SS 
values were found from the first day on, when compared with 
the baseline value (Day 1: p=0.001), and this was maintained 
until the end of the study.
According to the investigator, on Day 28, approximately 
45% of patients had significant or excellent improvement/
complete disappearance of symptoms, while 39.5% showed 
a slight improvement, and the rest of the patients showed no 
change or an increase.
No patient used rescue medication due to unacceptable 
severity of symptoms.
Discussion
The aim and strength of this study was to provide information 
regarding the safety and efficacy of rupatadine in very young 
children (2–5 years) suffering from AR. There is very little 
Table 2 Adverse events
Adverse drug event N=44
e (%)a/n (%)b
Ear pain 1 (6.7)/1 (2.3)
Conjunctivitis 2 (13.3)/2 (4.5)
Diarrhea 1 (6.7)/1 (2.3)
Mouth ulceration 1 (6.7)/1 (2.3)
Pyrexia 1 (6.7)/1 (2.3)
Oral herpes 1 (6.7)/1 (2.3)
Upper respiratory tract infection 1 (6.7)/1 (2.3)
Viral infection 3 (20.0)/2 (4.5)
Sunburn 1 (6.7)/1 (2.3)
Blood creatinine phosphokinase increased 1 (6.7)/1 (2.3)
Bronchospasm 1 (6.7)/1 (2.3)
Eczema 1 (6.7)/1 (2.3)


















Figure 1 Mean (SD) absolute T5SS values at baseline and Days 14 and 28.
Note: *p<0.001 compared to baseline.
Abbreviation: T5SS, Total Five Symptoms Score.
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published research on children diagnosed according with 
ARIA classification and treated with second-generation anti-
H1 compounds.16,17 Most of the available pediatric literature 
with antihistamines are published with seasonal or perennial 
AR in older children over 6 year old.18–22 In the other few pub-
lished studies in this very young population, old compounds 
that were launched in the market in the 1980s (eg, cetirizine 
and loratadine) were evaluated.12–14
Despite the lack of placebo, the percentage of improve-
ment in symptoms after 4 weeks of treatment (37.4%) is 
close to a major pivotal trial using the same endpoint with a 
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Figure 2 Mean (SD) absolute individual values in each symptom score at baseline and Days 14 and 28.
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Figure 3 Mean (SD) daily T5SS absolute values during 28 days.
Abbreviation: T5SS, Total Five Symptoms Score.





validation of the present data in very young children, thus 
enabling the conclusion that rupatadine oral solution may 
also be effective in this population of young children.16 
In addition, in the current study, all symptoms improved 
individually, at least an average 20% of improvement, even 
for nasal congestion. Moreover, the improvement obtained 
in T5SS after 28 days was somewhat higher than after 
14 days (mean value 26.6%), showing that there was no 
tachyphylaxis.
The majority of the patients included in our study were 
polysensitive, and most of them sensitive to house dust 
mite. This means that the allergies that affected this group 
of patients were less dependent on seasonality, and this con-
founding factor is not likely to have played a relevant role 
in the improvement of symptoms in our study. In addition, 
the study was performed over a short duration, during few 
weeks when no season changes occurred.
The absence of a placebo comparator and the open-label 
design are limitations of the study that could cause bias and 
be a confounding factor. It is very difficult to perform placebo 
comparative clinical trials in young children, as they usually 
face reticence from both the ethic committees or local health 
authorities, and this is even more so when the product has 
shown efficacy in a previous trial in children of a different age 
group.16 In the past, studies with placebo in infant children 
were accepted for other indications rather than allergic rhinitis, 
such as in the ETAC (atopic dermatitis) and EPAC (prevention 
of asthma) studies with cetirizine.23,24 In AR, there is only 1 
previous study that included placebo in AR in young children 
(2–6 years), along with cetirizine and montelukast.13 Another 
aspect that made the inclusion of a placebo group difficult 
was that the study objective was also pharmacokinetic, and 
the ethics committees considered that it was not appropriate 
to draw blood samples in very young children who underwent 
placebo treatment. Due to the difficulties in performing clini-
cal trials in children, in the past, doses have been extrapolated 
from those used in adults. Recently, a concept paper by the 
European Medicines Agency (EMA) has been issued in order 
to establish the basic principles of the scientific validity of the 
extrapolation concept (EMA/129698/2012). Although it is an 
accepted practice, it can lead to infra- or supra-dosification 
in these pediatric populations. Thus, well-designed efficacy 
trials remain the gold standard for demonstrating the efficacy 
of a drug in children.
This study shows that rupatadine 1 mg/mL oral solution 
was safe for administration in children aged 2–5 years. An 
overall 25% of the 44 involved children suffered an adverse 
event, but none of them was considered related to the study 
medication. 
Conclusion
This study showed that once-daily rupatadine oral solution 
was found to be safe and was correlated with an improve-
ment of AR symptoms in young children (2–5 years old) with 
a magnitude similar to that observed in older ones (6–11 
years old). Only very few second-generation antihistamines 
provide such consistency of data in very young pediatric 
patients, with a very low incidence of side effects.
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